Although anti-VEGF therapy is clinically helpful, as demonstrated by improved survival in cancer patients or visual acuity in age-related macular degeneration (AMD) patients [3,5], many of them are refractory to this therapy or develop severe side effects [6,7,8]. This evidence concerns the gene VEGFA and age-related macular degeneration.